3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
27
Neoplasm Metastasis
5
Advanced Solid Tumors
5
Stomach Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Advanced Solid Tumors (Excluding Breast Cancer)
2
Urologic Diseases
1
Spinocerebellar Degenerations
1
Solid Tumor Cancer
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Renal Insufficiency
1
Refractory Solid Tumors
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Lung Neoplasms
1
Liver Neoplasms
1
Liver Diseases
1
Kidney Neoplasms
1
Kidney Diseases
1
Head and Neck Neoplasms
1
HER2 IHC3+ Advanced Colorectal Cancer
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Desmoid Tumors
1
Interventions
pembrolizumab
3
Oxaliplatin
2
Leucovorin
2
Fluorouracil
2
vicriviroc
1
trifluridine tipiracil drug combination
1
spartalizumab
1
regorafenib
1
binimetinib
1
Nivolumab
1
Irinotecan
1
Fulvestrant
1
E7046
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Spinocerebellar Degenerations
×
trifluridine tipiracil drug combination
×
Clear all
NCT05328908
2025-08-13
RELATIVITY-123
Bristol-Myers Squibb
Phase 3
Terminated
770 enrolled